GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -703.70K | -707.90K | 128.10K | 128.60K | -124.30K |
| Total Other Revenue | 205.90K | 207.10K | 223.50K | 224.50K | 150.90K |
| Total Revenue | -497.80K | -500.80K | 351.60K | 353.10K | 26.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -497.80K | -500.80K | 351.60K | 353.10K | 26.70K |
| SG&A Expenses | 1.75M | 1.76M | 1.58M | 1.59M | 1.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.46M | 4.49M | 2.83M | 2.85M | 3.88M |
| Operating Income | -4.96M | -4.99M | -2.48M | -2.49M | -3.85M |
| Income Before Tax | -5.97M | -6.01M | -2.95M | -2.96M | -3.96M |
| Income Tax Expenses | 600.00 | 600.00 | 2.30K | 2.30K | -5.10K |
| Earnings from Continuing Operations | -5.97M | -6.01M | -2.95M | -2.96M | -3.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.97M | -6.01M | -2.95M | -2.96M | -3.95M |
| EBIT | -4.96M | -4.99M | -2.48M | -2.49M | -3.85M |
| EBITDA | -4.94M | -4.97M | -2.44M | -2.45M | -3.76M |
| EPS Basic | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 223.08M | 223.08M | 168.40M | 168.40M | 140.00M |
| Average Diluted Shares Outstanding | 223.08M | 223.08M | 168.40M | 168.40M | 140.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |